Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. (WINT) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · WINT · as of Jun 8, 2026
Activity summary
Buy transactions
1
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
Windtree Therapeutics, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
WINT insider buying and selling by quarter
WINT insider selling · WINT insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Recent insider transactions
WINT executive sell shares · WINT board member insider trading · WINT insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Oct 8, 2024 | Fraser Craig President and CEO · Director | Purchase | 5,431 | $5K | Form 4 |
| Sep 27, 2023 | Fraser Craig President and CEO · Director | Purchase | 2,500 | $3K | Form 4 |
| Sep 26, 2023 | Fraser Craig President and CEO · Director | Purchase | 2,500 | $2K | Form 4 |
| Aug 23, 2023 | Geffken Daniel E. Director | Award | 2,033 | — | Form 4 |
| Aug 23, 2023 | Williams Leslie J. Director | Award | 2,033 | — | Form 4 |
| Aug 23, 2023 | Strobeck Mark Director | Award | 2,300 | — | Form 4 |
| Aug 23, 2023 | SCOTT ROBERT A Director | Award | 2,033 | — | Form 4 |
| Aug 23, 2023 | Simonson Steven SVP, Chief Medical Officer | Award | 15,867 | — | Form 4 |
| Aug 23, 2023 | Curtis Eric SVP & COO | Award | 14,667 | — | Form 4 |
| Aug 23, 2023 | Fraser Craig President and CEO · Director | Award | 45,867 | — | Form 4 |
| Apr 26, 2023 | Fraser Craig President and CEO · Director | Purchase | 1,497 | $3K | Form 4 |
| Apr 25, 2023 | Fraser Craig President and CEO · Director | Purchase | 1,315 | $2K | Form 4 |
| Feb 28, 2023 | Simonson Steven SVP, Chief Medical Officer | Other | 100 | — | Form 4 |
| Feb 28, 2023 | Fraser Craig President and CEO · Director | Other | 334 | — | Form 4 |
| Feb 28, 2023 | Curtis Eric SVP & COO | Other | 99 | — | Form 4 |
| Feb 28, 2023 | CARMAN DIANE SVP & General Counsel | Other | 99 | — | Form 4 |
| Feb 22, 2023 | Huang James Director | Other | 1,112,308 | $157K | Form 4 |
| Jul 27, 2022 | Fraser Craig President and CEO | Purchase | 2,500 | $950 | Form 4 |
| Jul 26, 2022 | Hamill John P. SVP & CFO | Purchase | 3,000 | $1K | Form 4 |
| Jul 26, 2022 | Fraser Craig President and CEO | Purchase | 2,500 | $935 | Form 4 |
| Jun 30, 2022 | Fraser Craig President and CEO | Purchase | 4,500 | $2K | Form 4 |
| Jun 29, 2022 | Fraser Craig President and CEO | Purchase | 7,000 | $3K | Form 4 |
| Jun 7, 2022 | Williams Leslie J. Director | Award | 5,000 | — | Form 4 |
| Jun 7, 2022 | SCOTT ROBERT A Director | Award | 5,000 | — | Form 4 |
| Jun 7, 2022 | Huang James Director | Award | 5,000 | — | Form 4 |
Fraser Craig
President and CEO · Director
Date
Oct 8
Shares
5,431
Price
$0.91
Value
$5K
Fraser Craig
President and CEO · Director
Date
Sep 27
Shares
2,500
Price
$1.02
Value
$3K
Fraser Craig
President and CEO · Director
Date
Sep 26
Shares
2,500
Price
$0.90
Value
$2K
Simonson Steven
SVP, Chief Medical Officer
Date
Aug 23
Shares
15,867
Price
—
Value
—
Fraser Craig
President and CEO · Director
Date
Aug 23
Shares
45,867
Price
—
Value
—
Fraser Craig
President and CEO · Director
Date
Apr 26
Shares
1,497
Price
$1.77
Value
$3K
Fraser Craig
President and CEO · Director
Date
Apr 25
Shares
1,315
Price
$1.89
Value
$2K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About WINT insider trading
WINT insider trades
Windtree Therapeutics, Inc. (WINT) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including WINT. Over the past 12 months, 0 insiders have filed transactions with the SEC. WINT insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Windtree Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
WINT insider trading · 5 questionsThe insiders of Windtree Therapeutics, Inc. (WINT) include executives and directors such as WINT, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026